---
title: "Semaglutide & Tirzepatide"
canonical_url: https://peptidelibrary.app/library/semaglutide-tirzepatide
description: "Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Each is approved on its own; the combination is not approved, and both labels say use with another GLP-1 receptor agonist is not recommended."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Semaglutide & Tirzepatide

Semaglutide & Tirzepatide (also called GLP-1 vs dual GIP/GLP-1 comparison entry) is a research peptide in the GLP-1 Agonist class. This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Each is approved on its own; the combination is not approved, and both labels say use with another GLP-1 receptor agonist is not recommended.

Also known as: GLP-1 vs dual GIP/GLP-1 comparison entry.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: Approved incretin class overview
- Mechanism class: GLP-1 Agonist
- Development stage: Approved product
- Regulatory class: Research compound, not FDA-approved

## Mechanism

This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction. Tirzepatide activates both the GIP and GLP-1 receptors from a single peptide, with agonism weighted toward GIPR and biased signalling at GLP-1R that limits receptor desensitisation. The added GIP activity is the pharmacological difference, and head-to-head trial data in obesity has shown greater mean weight reduction with tirzepatide. Both are prescription medicines with class-typical gastrointestinal effects.

Targets: GLP-1 receptor, GIP receptor (tirzepatide).

Origin: Two separate approved peptide drugs.

## Properties

- Half-life: See individual products (~5–7 days)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with obesity, or overweight with a weight-related condition. Chronic weight management. Research on a related compound, not this one. Limitations: Studied an analog, not Semaglutide & Tirzepatide itself [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
2. ZEPBOUND (tirzepatide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with obesity, or overweight with at least one weight-related comorbid condition. Reduction and maintenance of body weight. Research on a related compound, not this one. Limitations: Studied an analog, not Semaglutide & Tirzepatide itself [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. 2021. Human study (early or uncontrolled). Population: Adults with type 2 diabetes (n=1,879). Research on a related compound, not this one. Limitations: Studied an analog, not Semaglutide & Tirzepatide itself [Source](https://pubmed.ncbi.nlm.nih.gov/34170647/)

## Safety

Side effects: Shared GI class effects.

Risks: Do not combine two GLP-1–class agonists without clinician direction.

Contraindications: Titrate slowly to manage GI effects; follow Rx guidance.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Semaglutide & Tirzepatide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: Prescription-Only

The library classification says "FDA-Approved" while the FDA status says Not Approved.

## Frequently asked questions

### What is Semaglutide & Tirzepatide?

Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.

### Is Semaglutide & Tirzepatide FDA approved?

Yes. Semaglutide & Tirzepatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Semaglutide & Tirzepatide?

Reported half-life for Semaglutide & Tirzepatide is See individual products (~5–7 days). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Semaglutide & Tirzepatide banned in sport?

Semaglutide & Tirzepatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Semaglutide & Tirzepatide?

Compounds most often compared with Semaglutide & Tirzepatide include Amycretin, CagriSema, Cotadutide and Dulaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Wegovy label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s015lbl.pdf)
- [Zepbound label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf)
- [Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies — Endocrinol Diabetes Metab, 2025](https://pubmed.ncbi.nlm.nih.gov/40184508/)
- [Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes — JAMA Netw Open, 2025](https://pubmed.ncbi.nlm.nih.gov/40788646/)
- [Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis — Front Pharmacol, 2025](https://pubmed.ncbi.nlm.nih.gov/40444045/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
